To The Moon

$Lantheus(LNTH)$ received US approval for a new Alzheimer’s imaging agent on August 14, but its shares barely moved because the company is already subject to a cash acquisition agreement. The more useful analysis therefore concerns merger economics: whether TAUKLARIFY improves the chance of receiving contingent payments and strengthens the strategic case for Curium’s proposed purchase.

The FDA approved TAUKLARIFY, also known as florquinitau F 18 or MK-6240, for PET brain imaging in cognitively impaired adults being evaluated for Alzheimer’s disease. The agent identifies tau neurofibrillary-tangle pathology and complements amyloid imaging, although a positive scan does not by itself confirm Alzheimer’s and performance may be weaker at earlier pathological stages.

Approval was supported by blinded-read studies involving more than 500 subjects. Lantheus announced the approval on August 14.

The bullish strategic case is that Lantheus is building a neurology-imaging franchise rather than relying solely on prostate-cancer imaging. Second-quarter Neuraceq sales were $39.6 million, while DEFINITY sales rose 5.2% to $88.3 million. Worldwide revenue increased 2.7% to $388.2 million, operating cash flow was $92.2 million and free cash flow was $89.9 million. Lantheus’s August 6 results provide the product figures.

The counterweight is PYLARIFY, the company’s largest product. Its quarterly sales declined 4.1% to $240.4 million. TAUKLARIFY also has no automatic commercial launch: management said it would support pharmaceutical research while assessing a broader route to market. Adoption depends on manufacturing, reimbursement, clinical guidelines and the development of Alzheimer’s therapies for which tau imaging changes treatment decisions.

Curium agreed on August 3 to pay $102.50 per Lantheus share in cash at closing, plus non-transferable contingent value rights worth up to $12. The CVR includes as much as $3 tied to global neurology-diagnostics sales thresholds through 2030, making TAUKLARIFY relevant to the contingent value even if near-term revenue is modest.

The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. The official merger announcement details each milestone and warns that no CVR payment is assured.

Lantheus closed at $100.95 on August 14, only $1.55 below the guaranteed cash consideration, after ranging from $100.85 to $101.39. That tight spread implies relatively high confidence in closing, while assigning limited present value to the CVR. The technical framework is therefore merger-driven: $100.50–$100.85 is near-term support, $102.50 is the cash-ceiling reference, and a sharp move below $100 would more likely signal deal concern than ordinary chart weakness.

The evidence leans moderately bullish on deal completion and neutral on incremental upside. TAUKLARIFY improves the neurology franchise and CVR logic, but commercial timing remains uncertain and most guaranteed value is already reflected in the price. The view would be invalidated by regulatory resistance to the merger, a revised closing timetable, poor reimbursement prospects or evidence that the neurology milestones are unreachable. This is personal opinion for education and is not financial advice.

@Tiger_SG @Tiger_comments @TigerStars @TigerClub @CaptainTiger @Daily_Discussion

Disclaimer: This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The views expressed are personal opinions based on publicly available information and are subject to change without notice. Investors should conduct their own research and consider their financial situation, risk tolerance, and investment objectives before making any investment decisions. I do not guarantee the accuracy or completeness of the information presented.